ES2610731T3 - Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios - Google Patents
Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios Download PDFInfo
- Publication number
- ES2610731T3 ES2610731T3 ES13002263.5T ES13002263T ES2610731T3 ES 2610731 T3 ES2610731 T3 ES 2610731T3 ES 13002263 T ES13002263 T ES 13002263T ES 2610731 T3 ES2610731 T3 ES 2610731T3
- Authority
- ES
- Spain
- Prior art keywords
- hpa
- antibody
- platelet
- platelets
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000961 alloantigen Effects 0.000 title claims abstract description 28
- 238000012360 testing method Methods 0.000 title description 121
- 238000000034 method Methods 0.000 claims abstract description 157
- 238000001514 detection method Methods 0.000 claims abstract description 68
- 210000004369 blood Anatomy 0.000 claims abstract description 32
- 239000008280 blood Substances 0.000 claims abstract description 32
- 238000009739 binding Methods 0.000 claims abstract description 18
- 239000012528 membrane Substances 0.000 claims description 64
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims description 47
- 102000057154 human ITGB3 Human genes 0.000 claims description 47
- 238000003556 assay Methods 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 230000004224 protection Effects 0.000 claims description 5
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 3
- 230000002934 lysing effect Effects 0.000 abstract description 2
- 230000003381 solubilizing effect Effects 0.000 abstract description 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 3
- 108090000288 Glycoproteins Proteins 0.000 abstract 3
- 210000001772 blood platelet Anatomy 0.000 description 225
- 239000000243 solution Substances 0.000 description 56
- 239000000523 sample Substances 0.000 description 49
- 239000000975 dye Substances 0.000 description 44
- 239000007788 liquid Substances 0.000 description 41
- 238000010521 absorption reaction Methods 0.000 description 37
- 238000005259 measurement Methods 0.000 description 35
- 239000003446 ligand Substances 0.000 description 33
- 229920003023 plastic Polymers 0.000 description 33
- 239000004033 plastic Substances 0.000 description 33
- 210000002381 plasma Anatomy 0.000 description 27
- 238000013019 agitation Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 21
- 230000005284 excitation Effects 0.000 description 21
- 230000003993 interaction Effects 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- -1 polypropylene Polymers 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 238000005406 washing Methods 0.000 description 13
- 238000002405 diagnostic procedure Methods 0.000 description 12
- 238000000576 coating method Methods 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 239000004793 Polystyrene Substances 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 201000005485 Toxoplasmosis Diseases 0.000 description 9
- 239000012491 analyte Substances 0.000 description 9
- 230000000702 anti-platelet effect Effects 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 9
- 238000001746 injection moulding Methods 0.000 description 9
- 229920002223 polystyrene Polymers 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 239000002981 blocking agent Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 6
- 229920003050 poly-cycloolefin Polymers 0.000 description 6
- 229920002239 polyacrylonitrile Polymers 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000001143 conditioned effect Effects 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 206010060935 Alloimmunisation Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010004469 allophycocyanin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005842 biochemical reaction Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010808 liquid waste Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012815 thermoplastic material Substances 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 235000012709 brilliant black BN Nutrition 0.000 description 2
- 239000004126 brilliant black BN Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940008228 intravenous immunoglobulins Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- GMMAPXRGRVJYJY-UHFFFAOYSA-J tetrasodium 4-acetamido-5-hydroxy-6-[[7-sulfonato-4-[(4-sulfonatophenyl)diazenyl]naphthalen-1-yl]diazenyl]naphthalene-1,7-disulfonate Chemical group [Na+].[Na+].[Na+].[Na+].OC1=C2C(NC(=O)C)=CC=C(S([O-])(=O)=O)C2=CC(S([O-])(=O)=O)=C1N=NC(C1=CC(=CC=C11)S([O-])(=O)=O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 GMMAPXRGRVJYJY-UHFFFAOYSA-J 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011300 routine therapy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13002263.5A EP2796880B1 (en) | 2013-04-26 | 2013-04-26 | Platelet allo-antigen typing and platelet antibody tests |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2610731T3 true ES2610731T3 (es) | 2017-05-03 |
Family
ID=48190069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13002263.5T Active ES2610731T3 (es) | 2013-04-26 | 2013-04-26 | Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios |
| ES14001772.4T Active ES2657236T3 (es) | 2013-04-26 | 2013-04-26 | Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14001772.4T Active ES2657236T3 (es) | 2013-04-26 | 2013-04-26 | Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160077089A1 (enExample) |
| EP (2) | EP2796880B1 (enExample) |
| JP (1) | JP2016524691A (enExample) |
| DK (2) | DK2796881T3 (enExample) |
| ES (2) | ES2610731T3 (enExample) |
| NO (1) | NO2796881T3 (enExample) |
| WO (1) | WO2014173546A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03655B (me) | 2014-03-31 | 2020-07-20 | Rallybio Ipa Llc | Antitijela protiv hpa-1a |
| US10725041B2 (en) * | 2014-11-04 | 2020-07-28 | Versiti Blood Research Institute Foundation, Inc. | Method to bioengineer designer platelets using gene editing and stem cell methodologies |
| CN106950385A (zh) * | 2017-05-23 | 2017-07-14 | 北京乐普医疗科技有限责任公司 | 一种血小板抗体检测试剂盒及其使用方法 |
| US20210041434A1 (en) * | 2019-08-06 | 2021-02-11 | Magarray, Inc. | Systems and Methods for Measuring Binding Kinetics of Analytes in Complex Solutions |
| CA3181176A1 (en) * | 2020-04-27 | 2021-11-04 | CCOA Therapeutics Inc. | Rapid and facile antibody detection using covalently immobilized self-assembled polypeptides |
| CN116577513B (zh) * | 2023-06-05 | 2024-09-24 | 中元汇吉生物技术股份有限公司 | 一种长期稳定的免疫比浊试剂及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE50010710D1 (de) * | 1999-08-20 | 2005-08-18 | Diagnostische Forsch Stiftung | Verfahren zur bestimmung von substanzen mittels der evaneszenzfeldmethode |
| DE59909185D1 (de) | 1999-08-24 | 2004-05-19 | Leuze Electronic Gmbh & Co Kg | Vorrichtung zur Durchführung von Immunoassays |
| DE10122806A1 (de) * | 2001-05-10 | 2002-11-14 | Holger Kiesewetter | Verfahren zum Nachweis von Blutzell-Antigenen und gegen diese gerichtete Antikörper |
| EP1371966A1 (en) * | 2002-06-14 | 2003-12-17 | Stiftung Für Diagnostische Forschung | A cuvette for a reader device for assaying substances using the evanescence field method |
| US20090317413A1 (en) * | 2005-11-15 | 2009-12-24 | Cambridge Enterprise Limited | Detection of human platelet antigen (hpa) antibodies |
| ES2345569T3 (es) * | 2006-02-07 | 2010-09-27 | Stiftung Fur Diagnostische Forschung | Peptido aptamero para neutralizar la union de anticuerpos especificos a antigenos plaquetarios y aplicaciones terapeuticas y de diagnostico que lo contienen. |
| EP2006304A1 (en) * | 2007-06-22 | 2008-12-24 | Stiftung Für Diagnostische Forschung | Anti-HPA-5b monoclonal antibody |
| JP5487127B2 (ja) * | 2011-01-14 | 2014-05-07 | 富士フイルム株式会社 | 測定装置およびセンサチップ |
| JP2012202742A (ja) * | 2011-03-24 | 2012-10-22 | Fujifilm Corp | 検出方法および検出装置 |
| WO2013013220A2 (en) * | 2011-07-20 | 2013-01-24 | University Of Washington Through Its Center For Commercialization | Photonic blood typing |
-
2013
- 2013-04-26 ES ES13002263.5T patent/ES2610731T3/es active Active
- 2013-04-26 DK DK14001772.4T patent/DK2796881T3/en active
- 2013-04-26 ES ES14001772.4T patent/ES2657236T3/es active Active
- 2013-04-26 NO NO14001772A patent/NO2796881T3/no unknown
- 2013-04-26 EP EP13002263.5A patent/EP2796880B1/en not_active Not-in-force
- 2013-04-26 EP EP14001772.4A patent/EP2796881B1/en not_active Not-in-force
- 2013-04-26 DK DK13002263.5T patent/DK2796880T3/en active
-
2014
- 2014-04-25 US US14/787,046 patent/US20160077089A1/en not_active Abandoned
- 2014-04-25 JP JP2016509327A patent/JP2016524691A/ja active Pending
- 2014-04-25 WO PCT/EP2014/001110 patent/WO2014173546A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2657236T3 (es) | 2018-03-02 |
| WO2014173546A2 (en) | 2014-10-30 |
| EP2796880A1 (en) | 2014-10-29 |
| NO2796881T3 (enExample) | 2018-03-31 |
| EP2796881B1 (en) | 2017-11-01 |
| EP2796881A1 (en) | 2014-10-29 |
| WO2014173546A3 (en) | 2015-01-08 |
| JP2016524691A (ja) | 2016-08-18 |
| US20160077089A1 (en) | 2016-03-17 |
| EP2796880B1 (en) | 2016-10-26 |
| DK2796880T3 (en) | 2017-01-16 |
| DK2796881T3 (en) | 2018-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2610731T3 (es) | Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios | |
| ES2702033T3 (es) | Amplificación de la señal en inmunoensayos | |
| ES2207757T3 (es) | Deteccion de igg especifica para antigenos. | |
| AU2020201874B2 (en) | Immunoassay utilizing trapping conjugate | |
| CN114910637B (zh) | 一种sIgE检测试剂盒及其检测方法 | |
| WO2008053822A1 (en) | Method of detecting specific bond reaction of molecule by single molecule fluorometry | |
| EP2639584A1 (en) | Real time diagnostic assays using an evanescence biosensor | |
| CN102239410B (zh) | 具有合并的对照和校准区的测试元件 | |
| ES2761427T3 (es) | Procedimientos para reducir interferencias | |
| ES2368776T3 (es) | MÉTODO PARA LA DETECCIÓN DE ANTICUERPOS ESPECÍFICOS DE LA CLASE DE INMUNOGLOBULINA G (IgG). | |
| CN106460056A (zh) | 新型试样内检测对象物的检测方法及利用其的检测试剂盒 | |
| US20230131780A1 (en) | Methods of detecting antibodies to sars-cov-2 | |
| CN109870581A (zh) | 一种定量检测HBsAg的试剂盒及方法 | |
| US20120208292A1 (en) | Fluorescent measurement in a disposable microfluidic device, and method thereof | |
| ES2796479T3 (es) | Procedimiento de pretratamiento para la detección rápida del antígeno central del VHC | |
| ES2321740T3 (es) | Procedimiento para la deteccion rapida y sencilla de celulas y biomoleculas con ayuda de particulas paramagneticas. | |
| WO2021221082A1 (ja) | ＳＡＲＳ－ＣｏＶ－２由来ヌクレオカプシド断片および該断片を用いて抗ＳＡＲＳ－ＣｏＶ－２抗体を検出する方法およびキット | |
| KR20230084469A (ko) | Sars-cov-2를 검출하기 위한 검정법 | |
| Henares et al. | Characterization of capillary immunosensor for capillary-assembled microchip (CAs-CHIP) integration | |
| EP4541895A1 (en) | Method for detecting analyte using polynucleotide | |
| EP3797867B1 (en) | Evanescence biosensor for blood | |
| US20130157378A1 (en) | Attenuating dye for interrogating multiple surfaces, and method thereof | |
| WO2025006602A1 (en) | Compositions and methods for detecting analytes in exosomes | |
| CA2859019A1 (en) | Fluorescent measurement in a disposable microfluidic device, and method thereof |